Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 plus Erlotinib in Advanced NSCLC
NCT01294306Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Feb 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01294306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294306.